Pacific Brain Tumor Center
Comprehensive Brain Tumor Care
At the Pacific Brain Tumor Center, we provide comprehensive care for patients with all types of brain tumors including benign and malignant brain tumors, skull base tumors, and metastatic brain tumors that arise from cancers elsewhere in the body.
Our multidisciplinary team of brain tumor experts—including neurosurgeons, ENT (head & neck – otolaryngology) surgeons, neuro-ophthalmologists, and neuro-oncologists—offers personalized precision treatment for each patient’s diagnosis. We treat even the most complex cases using advanced, minimally invasive brain tumor surgery techniques, including keyhole surgery and endoscopic approaches, to safely and effectively remove brain tumors while reducing recovery time.
With a compassionate, patient-first approach, we combine advanced imaging, surgical navigation tools, and targeted therapies to deliver effective treatment while restoring quality of life. We offer expert second opinions—in person or via telemedicine—for individuals already diagnosed, including patients in Greater Los Angeles, across the United States, and internationally.
Brain Tumors Treated by Our Specialists.
Our board-certified surgeons and specialists diagnose and treat all types of benign and malignant brain tumors.
Treatments and Procedures
With expertise in minimally invasive keyhole and endoscopic surgery, advanced brain cancer treatments and clinical trials, and stereotactic radiation therapy, our brain tumor specialists create personalized treatment plans based on each patient’s diagnosis, tumor type, and overall health—to help achieve the best possible outcomes.
Comprehensive Brain Tumor Services
Supportive Care Clinic
Our Supportive Care Clinic focuses on enhancing the quality of life for patients undergoing treatment for brain and skull base tumors. We provide comprehensive services, including symptom management and emotional support, tailored to address the unique challenges faced during and after treatment. Our multidisciplinary team collaborates to ensure that both patients and their families receive holistic care throughout the treatment journey.
Genomic Tumor Sequencing
We provide comprehensive tumor sequencing for surgically removed tumors. This includes options for whole genome analysis and tumor marker profiling, helping us personalize treatment based on each patient’s biology. We also collaborate with outside labs and institutions to facilitate advanced sequencing when needed.
Meet Our Expert Brain Tumor Surgeons & Specialists
Our team includes some of the nation’s top neurosurgeons, ENT (head & neck – otolaryngology) surgeons, neuro-ophthalmologists, and neuro-oncologists, all collaborating to deliver comprehensive, patient-centered care.
Brain Tumor Clinical Trials
At the Pacific Brain Tumor Center, we are committed to advancing care for brain and skull base tumors through clinical trials and ongoing research. We offer trials for patients with high-grade gliomas, metastatic brain cancers, and skull base tumors, often combining standard treatments with novel therapies.
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
A First in Human Study of AdAPT-001 in Subjects With Refractory Solid Tumors (BETA-PRIME)
This is the first clinical trial of AdAPT-001 for the treatment of cancer. AdAPT-001 is an oncolytic virus that is injected directly into the tumor. The purpose of this study is to find out the highest dose of AdAPT-001 that is safe and tolerable. This is the first step in studying whether it can be used to treat others with cancer in the future.
A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas (Expanded Access ONC028)
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma (Oral OKN-007)
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (Gliox; IORT)
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (CNS201)
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study; ONC108 ACTION)
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (Trident EF-32)
Pembrolizumab and Pemetrexed for Progressive Chordoma
Primary Objective: To determine objective response rate (ORR) according to RECIST v1.1 of pembrolizumab and high-dose pemetrexed in the treatment of patients with chordoma until disease progression. The OOR will be investigator assessed.
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies.
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence.
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (RESTORE)
This clinical trial is testing the safety and efficacy of NanO2™ administered via intravenous infusion in combination with standard radiation and chemotherapy.
NanO2™ is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Support That Goes Beyond Your Appointment
Details regarding insurance coverage and billing information are available at Providence.org.
Neurosurgery
- New Patient Questionnaire
- Appointment Instructions – What to Bring
- Records Release Form
- Surgery Instructions Overview
- Pre-operative Preparations
- Endonasal Discharge Instructions
- Craniotomy Discharge Instructions
- Post-operative Care
- Providence Preparing for Surgery Handbook
Neuro-oncology
Locations Serving Brain Tumor Patients

Request an Appointment
Contact Information
Saint John’s Health Center
2121 Santa Monica Blvd,
Garden Level, Santa Monica, CA 90404
310-829-8265
PNI-South Bay
5215 Torrance Blvd #300
Torrance, CA 90503
424-212-5361
PNI-Santa Monica
2125 Arizona Ave, 2nd Floor
Santa Monica, CA 90404
310-582-7450
Saint Joseph Medical Center – Neuro Clinic
501 S Buena Vista St
Burbank, CA 91505
818-847-6049
Disney Family Cancer Center
181 S. Buena Vista St
Burbank, CA 91505
818-847-6049
Saint Jude Medical Building
2151 N. Harbor Blvd #3100
Fullerton, CA 92835
714-446-5830
Saint Joseph Hospital Medical Building
1000 W. La Veta Ave
Orange, CA 92868
714-734-6294